Biotech Stocks: A Bumpy Ride to Recovery
Biotech stocks have had a rough time since their peak in early 2021. They didn't join the market's rebound in 2022, but this summer brought a change. These stocks are tricky because most of them are in the early stages of development. They often don't have earnings or steady revenue, relying instead on occasional milestone payments. This makes investing in them indiv...